Skip to main content

Immunic gets a "positive surprise" from lead asset trial

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.88
-0.09 (-0.04%)
AAPL  268.99
+0.18 (0.07%)
AMD  259.93
+0.25 (0.10%)
BAC  52.91
-0.11 (-0.20%)
GOOG  267.55
-2.38 (-0.88%)
META  748.43
-2.39 (-0.32%)
MSFT  543.35
+11.83 (2.23%)
NVDA  192.80
+1.31 (0.68%)
ORCL  283.09
+1.69 (0.60%)
TSLA  460.76
+8.34 (1.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.